Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of WPQW Granule for Overlap of Non-Erosive Reflux Disease(NERD) and Diarrhea Predominant Diarrhea Irritable Bowel Syndrome(IBS-D)

Non-erosive reflux disease(NERD)and Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)are both the common refractory gastrointestinal diseases. Patients, who suffered from overlapping symptoms of NERD and IBS-D, present more serious symptom manifestation, anxiety, and worse life quality than those with solely disease. There is lack of effective treatment for overlapping gastrointestinal symptoms. Traditional Chinese Medicine (TCM) syndrome differentiation and treatment has the advantages of overall regulation and individualized treatment, but lack of high-level evidence. The purpose of this study is to evaluate the efficacy and safety of WPQW granule for the treatment of NERD overlapping IBS-D.

Visão geral do estudo

Descrição detalhada

Gastroesophageal reflux disease (GERD) is a chronic relapsing acid-peptic disorder that is caused by the reflux of gastric or duodenum content. Non-erosive reflux disease(NERD), which account for 70%, is the most common type of GERD in the Asian population. Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)is the mainly subtype of IBS, and the prevalence was found to be 46% in IBS. Both diseases aforementioned are common and frequent chronic diseases in the world, and the pathogenesis of which has not been fully defined. Current studies have shown that GERD can present in patients with IBS, vice versa. Up to 79% of patients with IBS co-exist with GERD-like symptoms, and 71% of patients with GERD co-exist with IBS-like symptoms. For those patients, they suffer from more serious symptom manifestation, anxiety, and worse life quality those with solely disease. The diagnosis and treatment of Functional gastrointestinal disorders (FGIDs) mostly based on the idea of segmental diagnosis and single-target therapy in modern medicine, and there is lack of effective treatment for overlapping gastrointestinal symptoms. The advantages of holistic diagnosis therapy and individualized treatment in Traditional Chinese Medicine(TCM)have attracted international attention, but there is still lack of high-level evidence-based medical evidence for the treatment of symptom overlap in FGIDs in TCM. In this study, we propose to conduct a multicenter, randomized, double-blind, placebo-controlled clinical study of WPQW granule for the treatment of NERD overlapping IBS-D to evaluate the efficacy and safety of WPQW granule with the aim of obtaining high-level evidence-based medical evidence.

Tipo de estudo

Intervencional

Inscrição (Antecipado)

216

Estágio

  • Fase inicial 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Fengyun Wang, M.D
  • Número de telefone: +86(010)62835248
  • E-mail: wfy811@163.com

Locais de estudo

    • Beijing
      • Beijing, Beijing, China, 100091
        • Recrutamento
        • Xiyuan Hospital of China Academy of Chinese Medical Sciences
        • Contato:
          • Fengyun Wang, M.D
          • Número de telefone: +86(010)62835248
          • E-mail: wfy811@163.com

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Patients diagnosed with NERD and IBS-D simultaneously
  2. Patients who present cardinal symptoms like reflux, heartburn, abdominal pain/bloating, diarrhea, etc
  3. Patients diagnosed with syndrome of intermingled cold and heat of traditional Chinese medicine
  4. Patients have informed consent and are willing to receive corresponding treatment

Exclusion Criteria:

  1. Patients with hiatal hernia
  2. Patients with upper gastrointestinal bleeding, peptic ulcer, gastrointestinal tumor, chronic atrophic gastritis with dysplasia
  3. Patients with other serious organic diseases, such as acute cardiovascular disease, acute and chronic pancreatitis, cirrhosis, abnormal liver function (transaminases more than 1.5 times of normal value), abnormal thyroid function, diabetes mellitus with a history of more than 10 years, chronic renal insufficiency, hematologic disorders, and hematologic disorders, etc
  4. Patients with neurological disease or psychiatric impairment like severe anxiety, depression requiring long-term drug treatment
  5. Patients who cannot stop taking acid suppressants for a long time
  6. Alcohol or drug dependency or abuse
  7. Pregnant or lactating women
  8. Patients who have a history of allergies to all the test drugs
  9. Patients who are participating in other clinical trials or have participated in other clinical trials within 3 months
  10. Patients who, in the opinion of the investigator, are not suitable to participate in clinical trial

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Experimental group
Oral administration of WPQW granule with warm water,2 sachets each time, 3 times a day, 1.5-2 hours after a meal. The medication period was 4 weeks.
WPQW granule, 2 sachets / time, 3 times / day.
Comparador de Placebo: Control group
Oral administration of WPQW granule simulant,which containing 5% WPQW granule,with warm water,2 sachets each time, 3 times a day, 1.5-2 hours after a meal. The medication period was 4 weeks.
WPQW granule simulant, 2 sachets / time, 3 times / day.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change of visual analogue scale (VAS) score of symptoms of reflux and heartburn
Prazo: baseline, 4 weeks during treatment period, 4 weeks during follow-up period
During the medication period, the patients recorded the reflux and heartburn episodes (frequency and duration) within 24 hours per day on the symptom diary card, and VAS scores for reflux and heartburn symptoms was calculated as the mean score of each symptom in the past week. The episodes in the week before medication were used as the baseline, the mean score of any symptom decreased ≥50% from the baseline was recorded as response after weekly treatment, and the number of response weeks was considered effective if it was greater than 50% of the weeks of the whole treatment period.
baseline, 4 weeks during treatment period, 4 weeks during follow-up period
Change of visual analogue scale (VAS) score of symptoms of abdominal pain and diarrhea
Prazo: baseline, 4 weeks during treatment period, 4 weeks during follow-up period
During the medication period, the patients recorded the of abdominal pain (pain severity and frequency) and diarrhea (stool consistency and frequency based on Bristol stool form scale) within 24 hours per day on the symptom diary card. VAS score was conducted for the most severe abdominal pain, and the mean score was calculated for each week, with the week of episodes prior to medication administration as the baseline. It was considered effective when the weekly mean score decrease of at least 30% from baseline and the days of at least once type 6 or type 7 stool Bristol stool form every week decrease of at least 30% from baseline, referring to the efficacy evaluation of the technical guidelines for clinical studies of Chinese medicine for IBS published in 2017.
baseline, 4 weeks during treatment period, 4 weeks during follow-up period

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change of traditional Chinese Medicine syndrome score
Prazo: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
The symptoms related to syndrome of intermingled cold and heat were scored. The cardinal symptom was scored 0, 2, 4, 6 and the secondary symptom scored 0, 1, 2, 3 respectively according to severity of each symptom. Total symptom score represented the syndrome score. Reduction in syndrome score represented Improvement.
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Change of 36-item short-form (SF-36) score
Prazo: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Health status was evaluated by a 36-item short-form (SF-36) containing eight health concepts. If the score descends, it indicates that the patient's condition has improved.
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Change of FGI-checklist score
Prazo: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
A 20-item FGI-checklist was used to evaluate comprehensive symptom severity of Functional Gastrointestinal Disorder (FGID), which covering esophageal, dyspeptic and bowel symptoms. If the score descends, it indicates that the patient's condition has improved.
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Change of Hospital Anxiety and Depression Scale (HAD) score
Prazo: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Hospital Anxiety and Depression Scale (HAD) score was used to evaluate the efficacy of experimental drug. Reduction in total score represented Improvement
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de dezembro de 2021

Conclusão Primária (Antecipado)

1 de maio de 2023

Conclusão do estudo (Antecipado)

1 de maio de 2023

Datas de inscrição no estudo

Enviado pela primeira vez

8 de maio de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de maio de 2022

Primeira postagem (Real)

11 de maio de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

11 de maio de 2022

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de maio de 2022

Última verificação

1 de dezembro de 2021

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever